Market Research Logo

Osteosarcoma - Pipeline Review, H2 2016

Osteosarcoma - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Osteosarcoma - Pipeline Review, H2 2016’, provides an overview of the Osteosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Osteosarcoma
    • The report reviews pipeline therapeutics for Osteosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Osteosarcoma therapeutics and enlists all their major and minor projects
    • The report assesses Osteosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Osteosarcoma
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Osteosarcoma
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Osteosarcoma Overview
    Therapeutics Development
    Pipeline Products for Osteosarcoma - Overview
    Pipeline Products for Osteosarcoma - Comparative Analysis
    Osteosarcoma - Therapeutics under Development by Companies
    Osteosarcoma - Therapeutics under Investigation by Universities/Institutes
    Osteosarcoma - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Osteosarcoma - Products under Development by Companies
    Osteosarcoma - Products under Investigation by Universities/Institutes
    Osteosarcoma - Companies Involved in Therapeutics Development
    Advaxis, Inc.
    Amgen Inc.
    AVEO Pharmaceuticals, Inc.
    Bayer AG
    Bellicum Pharmaceuticals, Inc.
    Celldex Therapeutics, Inc.
    CytRx Corporation
    Eleison Pharmaceuticals LLC
    Exelixis, Inc.
    Isofol Medical AB
    MediaPharma s.r.l.
    Merck & Co., Inc.
    Merrimack Pharmaceuticals, Inc.
    Netris Pharma S.A.S.
    Novartis AG
    Oncolys BioPharma Inc
    Pfizer Inc.
    Shionogi & Co., Ltd.
    Teijin Pharma Limited
    United Therapeutics Corporation
    Osteosarcoma - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    3D-QM - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    3D-QMS - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ADXS-HER2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    aldoxorubicin hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AM-7209 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AU-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AV-203 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    axitinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cabozantinib s-malate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    celyvir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CGS-200 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cisplatin SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dihydroartemisinin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dinutuximab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    everolimus - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    glembatumumab vedotin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    irinotecan hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ligerin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LLL-12 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Modufolin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for Osteosarcoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MPE-8.3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NP-137 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OBP-702 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pazopanib hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pembrolizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    radium Ra 223 dichloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RSF-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-588410 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SEN-461 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    T-2GES - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Osteosarcoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Osteosarcoma - Dormant Projects
    Osteosarcoma - Discontinued Products
    Osteosarcoma - Product Development Milestones
    Featured News & Press Releases
    Apr 28, 2016: FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma
    Apr 20, 2016: Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin at the AACR Annual Meeting 2016
    Apr 13, 2016: Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform
    Mar 23, 2016: Advaxis Hosts Research Reception to Review Late-Breaking ADXS-HER2 at AACR Abstract
    Mar 21, 2016: Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research
    Mar 16, 2016: Merrimack to Present on ONIVYDE (irinotecan liposome injection) at the 2016 American Association for Cancer Research Annual Meeting
    Jan 19, 2016: Advaxis Expands Intellectual Property for Lm Technology Platform
    Dec 01, 2015: Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma
    Nov 30, 2015: CapGenesis Files Five Orphan Drug Designation Requests with the FDA and EMA for CGS-200 as a Topical Analgesic
    Jul 21, 2015: Advaxis Expands Intellectual Property for Lm Technology Platform in HER2
    May 04, 2015: CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers
    May 01, 2015: Eleison Announces Successful Completion of Stage 1 of its Phase II Trial of ILC (Inhaled Lipid-complexed Cisplatin) for Pediatric Bone Cancer
    Apr 28, 2015: Advaxis Enhances Lm-LLO Cancer Immunotherapy Intellectual Property With USPTO Patent Addressing ADXS-HER2
    Nov 04, 2014: Advaxis to Present Data of ADXS-cHER2 at the Society for Immunotherapy of Cancer 29th Annual Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Osteosarcoma, H2 2016
    Number of Products under Development for Osteosarcoma - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Osteosarcoma - Pipeline by Advaxis, Inc., H2 2016
    Osteosarcoma - Pipeline by Amgen Inc., H2 2016
    Osteosarcoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
    Osteosarcoma - Pipeline by Bayer AG, H2 2016
    Osteosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
    Osteosarcoma - Pipeline by Celldex Therapeutics, Inc., H2 2016
    Osteosarcoma - Pipeline by CytRx Corporation, H2 2016
    Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H2 2016
    Osteosarcoma - Pipeline by Exelixis, Inc., H2 2016
    Osteosarcoma - Pipeline by Isofol Medical AB, H2 2016
    Osteosarcoma - Pipeline by MediaPharma s.r.l., H2 2016
    Osteosarcoma - Pipeline by Merck & Co., Inc., H2 2016
    Osteosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
    Osteosarcoma - Pipeline by Netris Pharma S.A.S., H2 2016
    Osteosarcoma - Pipeline by Novartis AG, H2 2016
    Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H2 2016
    Osteosarcoma - Pipeline by Pfizer Inc., H2 2016
    Osteosarcoma - Pipeline by Shionogi & Co., Ltd., H2 2016
    Osteosarcoma - Pipeline by Teijin Pharma Limited, H2 2016
    Osteosarcoma - Pipeline by United Therapeutics Corporation, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Osteosarcoma - Dormant Projects, H2 2016
    Osteosarcoma - Dormant Projects (Contd..1), H2 2016
    Osteosarcoma - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Osteosarcoma, H2 2016
    Number of Products under Development for Osteosarcoma - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report